Marisa Wexler, MS, senior science writer —

People with sarcoidosis who have impaired lung function seem to be at greater risk for severe COVID-19 disease, a new study suggests. The study, “Moderate or Severe Impairment in Pulmonary Function is Associated with Mortality in Sarcoidosis Patients Infected with SARS‑CoV‑2,” was published in the journal …

A grant from the Foundation for Sarcoidosis Research (FSR) will fund the development of a new mouse model of sarcoidosis, which could aid in understanding how the disease develops and ultimately serve as a platform for testing potential treatments. The FSR’s Small Grant program provides up to $25,000…

Protalix BioTherapeutics and SarcoMed USA have entered into a non-binding agreement related to the development and commercialization of PRX-110 (alidornase alfa) for pulmonary sarcoidosis and related diseases, according to a Protalix press release. PRX-110 is currently being developed by Protalix as a potential therapy for…

People with sarcoidosis-associated pulmonary hypertension who have reduced physical fitness or worse gas exchange capacity live significantly shorter times without requiring a transplant, a new study indicates. The study, “Physiological Predictors of Survival in Patients with Sarcoidosis Associated Pulmonary Hypertension,” was published in the European Respiratory…

Sarcoidosis affecting the spinal cord tends to result in distinct patterns visible on MRIs of the spine, which may help in properly diagnosing this disease type, a new study reports. The study, “Clinical and MRI phenotypes of sarcoidosis-associated myelopathy,” was published in the journal Neurology Neuroimmunology…

The American Thoracic Society has published its first official guidelines for how best to detect and diagnosis sarcoidosis in clinical practice. The guidelines were published in the American Journal of Respiratory and Critical Care Medicine, in an article titled “Diagnosis and Detection of Sarcoidosis. An Official American…

Results of a Phase 1b/2a clinical study evaluating ATYR1923 in people with pulmonary sarcoidosis are likely to be delayed due to the COVID-19 pandemic, its developer, aTyr Pharma, announced. ATYR1923 is a first-in-class therapy being developed to possibly different types of interstitial lung diseases (ILDs) — a…

Boehringer Ingelheim‘s Ofev (nintedanib) has been approved in the U.S. as the first treatment for chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype. This approval by the United States Food and Drug Administration (FDA) includes sarcoidosis, autoimmune ILDs, unclassifiable ILDs, chronic hypersensitivity pneumonitis,…

aTyr Pharma announced a collaboration and license agreement with Kyorin Pharmaceutical to develop and commercialize ATYR1923, its potential disease-modifying treatment for those with interstitial lung diseases (ILDs), including pulmonary sarcoidosis, in Japan. ATYR1923 is a fusion protein that contains a portion of a human antibody linked to…

Acthar Gel (repository corticotropin injection, or RCI) can improve sarcoidosis symptoms, a real-world study shows. Titled “Repository corticotropin injection in patients with advanced symptomatic sarcoidosis: retrospective analysis of medical records,” the study was published in the journal Therapeutic Advances in Respiratory Disease. Acthar Gel, marketed…